首页> 外文期刊>Kaohsiung Journal of Medical Sciences >Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A?systematic review and meta-analysis
【24h】

Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A?systematic review and meta-analysis

机译:氟喹诺酮预防预防肾移植术后BK多瘤病毒感染的系统评价和荟萃分析

获取原文
           

摘要

Previous studies regarding the prevention of BK viremia following renal transplantation with fluoroquinolone have yielded conflicting results. The purpose of this systematic review was to examine the evidence regarding the efficacy of fluoroquinolone in preventing BK polyomavirus infection following renal transplantation. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for research articles published prior to January 2015 using keywords such as “fluoroquinolone,” “BK viremia,” and “renal transplantation.” We extracted all types of study published in English. The primary outcome was BK viremia and viruria at 1?year post-transplantation. Secondary outcomes were BK virus-associated nephropathy (BKVN), graft failure, and fluoroquinolone-resistant infection. We identified eight trials, including a total of 1477 participants with a mean duration of fluoroquinolone prophylaxis of 1?month. At 1?year, fluoroquinolone prophylaxis was not associated with a decreased incidence of BK viremia [risk ratio (RR), 0.84; 95% confidence interval (95% CI), 0.58–1.20). No significant differences in BKVN (RR, 0.88; 95% CI, 0.37–2.11), risk of graft failure due to BKVN (RR, 0.68; 95% CI, 0.29–1.59), or fluoroquinolone-resistant infection (RR, 1.08; 95% CI, 0.64–1.83) were observed between the fluoroquinolone prophylaxis and control groups. The results of this study suggest that fluoroquinolone is ineffective in preventing BK polyomavirus infection following renal transplantation.
机译:先前有关用氟喹诺酮肾移植预防BK病毒血症的研究产生了矛盾的结果。该系统评价的目的是检查有关氟喹诺酮预防肾移植术后BK多瘤病毒感染的功效的证据。我们在PubMed,Embase和对照试验的Cochrane中央登记册中搜索了使用“氟喹诺酮”,“ BK病毒血症”和“肾移植”等关键字在2015年1月之前发布的研究文章。我们提取了所有以英语发布的研究类型。移植后1年的主要结果是BK病毒血症和病毒血症。次要结果是BK病毒相关性肾病(BKVN),移植失败和氟喹诺酮耐药性感染。我们确定了八项试验,包括总共1477名参与者,氟喹诺酮类药物的平均预防时间超过1个月。在1年时,预防氟喹诺酮与降低BK病毒血症的发生率无关[风险比(RR)为0.84; 95%置信区间(95%CI),0.58-1.20)。 BKVN(RR,0.88; 95%CI,0.37–2.11),因BKVN导致移植失败的风险(RR,0.68; 95%CI,0.29–1.59)或对氟喹诺酮耐药的感染(RR,1.08;在预防氟喹诺酮和对照组之间,观察到95%CI,0.64–1.83)。这项研究的结果表明,氟喹诺酮在预防肾移植术后BK多瘤病毒感染方面无效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号